Sunovion scores on PhIII Parkinson's study, shooting for showdown with Acorda; Puma out-licenses neratinib to Israeli biotech
→ Sunovion Pharmaceuticals has posted positive top-line data from their Phase III study for OFF episodes of Parkinson’s disease. According to researchers apomorphine hit the primary: a statistically significant mean reduction in the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III score. They added that the drug also scored on a key secondary. Sunovion now plans to hustle the drug to the FDA soon, which may well set up a confrontation with a rival drug from the struggling Acorda $ACOR, now rumored to be on the sales block.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.